ACADIA Pharmaceuticals Inc.

ACAD

$27.86

-0.02%

2026-09-04 12:07:59 EDT-$0.00

Healthcare

Biotechnology

NASDAQ

Active Trading

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies ...

Price Action of ACAD

$27.86

-0.02%+$0.00

High—

Low—

52W High-10.0%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

ACADIA Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company headquartered in San Diego, California, with a rich history dating back to its founding in 1993 as Receptor Technologies. The company has evolved into a leader in neuroscience and rare disease therapeutics, with a clear mission to elevate life for patients facing ...ACADIA Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company headquartered in San Diego, California, with a rich history dating back to its founding in 1993 as Receptor Technologies. The company has evolved into a leader in neuroscience and rare disease therapeutics, with a clear mission to elevate life for patients facing critical unmet medical needs. Its flagship product, NUPLAZID (pimavanserin), is the first and only treatment approved for hallucinations and delusions associated with Parkinson's disease psychosis, addressing a significant need in this patient population. The company has also launched DAYBUE (trofinetide) for the treatment of Rett syndrome, which highlights its expansion into rare diseases. Business-wise, ACADIA has demonstrated strong commercial performance, with a market cap around $5 billion and growing revenue. Its financial health is robust, with a net profit margin of 33.4% and a healthy balance sheet, including minimal debt and strong liquidity ratios (current ratio 3.388). The company invests heavily in R&D (research and development expense is about 29% of revenue), reflecting its commitment to innovation. Its pipeline is diverse, with pimavanserin in Phase 3 for Alzheimer's disease psychosis and negative symptoms of schizophrenia, trofinetide in Phase 3 for Rett syndrome (already approved as DAYBUE), and early-stage programs such as ACP-044 (an analgesic) and ACP-319 (a muscarinic modulator). Key leadership includes CEO Catherine Owen Adams, who brings over 25 years of executive experience, and a team dedicated to advancing neuroscience. The company's culture emphasizes patient-centricity, and it continues to explore new therapeutic avenues to 'redefine care' for patients with few or no treatment options.ExpandCollapse

Founded

1993

Employees

797

CEO

Catherine E. Owen Adams

Full Name

ACADIA Pharmaceuticals Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

32.39%

Market Cap

$4.80B

Current Ratio

3.39

WACC

8.46%

ROIC

30.99%

Contact Information

https://www.acadia.com

858 558 2871

12830 El Camino Real, San Diego, CA 92130

Key Metrics of ACAD

Snapshot

Latest / TTM · 6 periods

Market Cap

$4.80B

ROCE

6.3%

EV / EBITDA

38.40x

-1.9% YoY

FCF Yield

3.7%

+1.3% YoY

Cash Conversion Cycle

9.2d

Current Ratio

3.39

Quick take

TTM —

Positive CCC

Financial Highlights of ACAD

Profitability trend

Latest / TTM · 6 periods

Gross Margin

91.1%

Net Margin

33.4%

P/E Ratio

12.38x

n/a

Debt / Equity

0.06

n/a

Current Ratio

3.39

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of ACAD

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $0.20 · Revenue $332.29M · 11 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $0.22 · Revenue $362.68M · 10 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $0.61 · Revenue $1.27B · 14 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $0.21 · Revenue $350.18M · 8 analysts

Recent history

Aug 5, 2026
Q2 FY2026 · Results reported
EPS $0.18 · Revenue $307.96M
View filing
May 7, 2026
Q1 FY2026 · Results reported
EPS $0.02 · Revenue $268.06M
View filing
Feb 26, 2026
FY2025 · Annual results
EPS $2.29 · Revenue $1.07B
View filing
Nov 6, 2025
Q3 FY2025 · Results reported
EPS $0.42 · Revenue $278.63M
View filing
Aug 7, 2025
Q2 FY2025 · Results reported
EPS $0.16 · Revenue $264.57M
View filing
May 8, 2025
Q1 FY2025 · Results reported
EPS $0.11 · Revenue $244.32M
View filing

Financial Statements of ACAD

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$1.1B	+11.9%	+14.9%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$391.0M	+72.7%	+766.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+91.7%	+0.3%	+0.1%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+9.8%	-59.4%	+813.5%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	+36.5%	+54.3%	+653.9%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$105.1M	-33.1%	+332.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+9.8%	-40.2%	+276.6%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	4.3%	-40.1%	+38.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	3.83x	+61.3%	-5.6%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$1.6B	+31.7%	+8.6%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	2.29 vs 0.81	+183.0%	0.18 vs 0.07	+164.1%
Revenue Surprise	$1.1B vs $1.1B	-0.9%	$308.0M vs $296.6M	+3.8%

Insider Transactions of ACAD

Acquisitions (A)

Since Jul 29, 2026

Disposals (D)

Since Jul 29, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 6, 2026	Schneyer Mark C.	officer: EVP, CHIEF FINANCIAL OFFICER	Common Stock	A	14,292	$17.84
Aug 6, 2026	Schneyer Mark C.	officer: EVP, CHIEF FINANCIAL OFFICER	Common Stock	D	5,000	$29.00
Aug 6, 2026	Schneyer Mark C.	officer: EVP, CHIEF FINANCIAL OFFICER	Common Stock	D	9,292	$29.34
Aug 6, 2026	Schneyer Mark C.	officer: EVP, CHIEF FINANCIAL OFFICER	Stock Option (Right to Buy)	D	14,292	$17.84
Aug 5, 2026	Schneyer Mark C.	officer: EVP, CHIEF FINANCIAL OFFICER	Stock Option (Right to Buy)	D	5,849	$17.84

Earnings Call Transcript of ACAD

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Ladies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to ACADIA Pharmaceuticals Second Quarter 2026 Earnings Conference Call. [Operator Instructions] And I would now like to turn the conference over to Albert Kildani, Senior Vice President, Investor Relations and Corporate Development. Please go ahead. Albert Kildani: Good afternoon, and thank you for joining us on today's call to discuss ACADIA's second quarter 2026 financial results. Joining me on the call today from ACADIA are Catherine Owen Adams, our Chief Executive Officer, who will provide some opening remarks; followed by Tom Garner, our Chief Commercial Officer, who will discuss our commercial brands, DAYBUE and NUPLAZID. Also joining us today is Elizabeth Thompson, PhD, Executive Vice President, Head of Research and Development, who will provide an update on our pipeline programs; and Mark Schneyer, our Chief Financial Officer, who will review the financial highlights. Catherine will then provide some closing remarks before we open up the call for your questions. We are using supplemental slides, which are available on our website in the Events and Presentations section. On today's call, both GAAP and non-GAAP financial measures will be discussed, including non-GAAP NUPLAZID net sales and non-GAAP total revenues. The non-GAAP financial measures that are also referred to as adjusted financial measures pertain only to NUPLAZID sales in 2025 and their impact on total revenues. All references to non-GAAP are reconciled with the most directly comparable GAAP financial measures in our earnings press release and slide presentation, which has been posted on the Investors page of the company's website. Before proceeding, I'd like to remind you that during our call today, we will be making several forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including goals, expectations, plans, prospects, growth potential, timing of events, future results and financial guidance are based on current information, assumptions and expectations that are inherently subject to change and involve several risks and uncertainties that may cause results to differ materially. These factors and other risks associated with our business can be found in our filings made with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of today's date, and we assume no obligation to update or revise these forward-looking statements as circumstances change, except as required by law. I'll now turn the call over to Catherine for opening remarks. Catherine Owen Adams: Thank you, Al. Good afternoon, everyone, and thank you for joining us today. I'm pleased to report that ACADIA delivered an outstanding second quarter, demonstrating strong commercial execution across both …

Leadership Team of ACAD

11 executives

Name	Title	Compensation	Gender	Year Born	Status
Catherine E. Owen Adams	Chief Executive Officer & Director	USD 1,781,163	Female	1970	Active
Elizabeth Thompson	Executive Vice President and Head of Research & Development	USD 1,038,814	—	1976	Active
Mark C. Schneyer	Executive Vice President & Chief Financial Officer	USD 877,943	Male	1974	Active
Jennifer J. Rhodes	Executive Vice President, Chief Legal Officer & Secretary	USD 857,877	Female	1970	Active
Thomas Andrew Garner	Executive Vice President & Chief Commercial Officer	USD 857,023	Male	1976	Active
Carl Segerstrom	Chief People Officer	—	Male	—	Active
Allyson McMillan Youngblood	Senior Vice President of Rare Disease Franchise	—	Female	—	Active
Scott Cenci	Senior Vice President, Chief Information & Data Officer	—	Male	—	Active
Albert S. Kildani	Senior Vice President of Investor Relations & Corporate Communications	—	Male	—	Active
James K. Kihara	Senior Vice President of Finance	—	Male	1981	Active
Konstantina Katcheves	Senior Vice President, Chief Business & Strategy Officer	—	Female	—	Active

Recent News of ACAD

Zacks Investment ResearchyesterdayNeutral

Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Defense World3 days agoNeutral

Alyeska Investment Group L.P. Purchases Shares of 310,287 ACADIA Pharmaceuticals Inc. $ACAD

Alyeska Investment Group L.P. purchased a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 310,287 shares of the biopharmaceutical company's stock, valued at approximately $7,850,000. Alyeska Investment Group L.P. owned about 0.18% of ACADIA

Zacks Investment Research8/24/2026Neutral

Acadia Gets European Commission Nod for Daybu in Rett Syndrome

ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.

GuruFocus8/24/2026Neutral

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the

Defense World8/24/2026Neutral

BlackRock Inc. Purchases Shares of 22,515,173 ACADIA Pharmaceuticals Inc. $ACAD

BlackRock Inc. acquired a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,515,173 shares of the biopharmaceutical company's stock, valued at approximately $569,634,000. BlackRock Inc. owned 13.15% of ACADIA Pharmaceuticals

Historical Employee Count of ACAD

Current

653

Change

+9.38%

Minimum

511

Maximum

653

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2024	653	10-K	Feb 27, 2025	View
Dec 31, 2023	597	10-K	Feb 28, 2024	View
Dec 31, 2022	511	10-K	Feb 28, 2023	View
Dec 31, 2021	512	10-K	Mar 1, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

ACADIA Pharmaceuticals Inc.